About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Roche Teams Up With Swiss Company to Develop Superbug Killer

by Savitha C Muppala on November 5, 2013 at 1:34 PM
Font : A-A+

 Roche Teams Up With Swiss Company to Develop Superbug Killer

Pharmaceuticals giant Roche has teamed up with Swiss company Polyphor to develop an antibiotic that can effectively deal with a superbug that has taken hold in hospitals.

Hospital-acquired infections are a major global concern, causing 25,000 deaths a year in the European Union alone.

Advertisement

They are blamed on factors such as sloppy hygiene practices, the inappropriate use of drugs which has enabled resistant bacteria to thrive, and contact between humans and animals, either directly or via the food chain.

In a statement, Roche said that it had signed an exclusive worldwide licensing agreement with Polyphor to develop and commercialise the latter's experimental antibiotic POL7080.
Advertisement

The drug's target is the Pseudomonas aeruginosa bacteria, which can give rise to life-threatening infections and usually occurs in patients in hospital, as well as members of the broader public who have weakened immune systems.

Pseudomonas aeruginosa accounts for one in every 10 hospital-acquired infections in the United States and is listed as one of the six most dangerous drug-resistant microbes.

It causes infections of the urinary tract, respiratory system infections, joints and bones, and digestive system.

Roche underlined that it was a particular danger for patients with cancer, AIDS, severe burns, and chronic infections such as cystic fibrosis, and had a 50-percent fatality rate in some of those groups.

Generally treated with traditional antibiotics, it has become more difficult to treat because of rising antibiotic resistance, Roche said.

Under the terms of the deal, Roche is to make an initial payment of 35 million Swiss francs (28.4 million euros, $38.4 million) to Polyphor, which is not listed in the stock exchange.

Provided certain development, regulatory and commercial milestones are reached, Roche's total payments could reach 465 million Swiss francs, it said.

In addition, Polyphor is entitled to receive double-digit royalties on product sales.

Source: AFP
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Health Benefits of Giloy
Breast Cancer Awareness Month 2021 - It's time to RISE
First-Ever Successful Pig-To-Human Kidney Transplantation
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
MRSA - The Super Bug Drug Resistance - Antibiotic Resistance 

Recommended Reading
Bacteria-Eating Viruses to be Used in the War on Superbugs
Viruses that eat bacteria have been isolated to specifically target the highly infectious hospital ....
Better Use of Antibiotics Could Help Fight the Superbugs
Proper use of antibiotics could help fight the infection Clostridium difficile - the superbug. ...
Keys to Antibiotic Resistance in Superbug Uncovered
New study conducted by scientists shows how MRSA regulates the critical crosslinking of its cell ......
Drug Resistance - Antibiotic Resistance
Drug resistance is often a problem in malaria, tuberculosis, HIV, sexually transmitted diseases and ...
MRSA - The Super Bug
MRSA infection is the most dreaded hospital or community acquired infection that can become ......

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use